$JAGX News

Jaguar Health, Inc. (JAGX) Q1 2026 Earnings Call Prepared Remarks Transcript

Jaguar Health Inc (NASDAQ:JAGX) Swings to Profit on Licensing Deal, But Market Sells the News

Jaguar Health Q1 EPS $(13.60) Misses $(4.26) Estimate, Sales $20.272M Beat $4.211M Estimate

Jaguar Health's Napo Pharmaceuticals Announces That First Patient From Cohort Of Pediatric MVID Patients Has Entered The Active Treatment Only Single-Blind Extension To Study Safety And Efficacy

Jaguar Health Stock Surges On FDA Breakthrough Discussions For Rare Disease Therapy

Jaguar Health Unit Napo Pharmaceuticals Announces Preliminary Discussion With FDA Division Of Gastroenterology Regarding The Possibility Of A Breakthrough Therapy Designation For Oral Liquid Crofelemer

Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs

Jaguar Health Announces Its Canalevia-CA1 To Treat Chemotherapy-Induced Diarrhea In Dogs Demonstrated Effective Results At End of 3-Day Treatment

Jaguar Health shares are trading lower after the company announced a 1-for-35 reverse stock split.

Jaguar Health shares are trading lower after the company announced a 1-for-35 reverse stock split.

Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split

Jaguar Health Announces 1-For-35 Reverse Stock Split, Effective April 30

Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)

Jaguar Health Announces Acceptance Of Two Late Breaking Abstracts To Treat Pediatric Intestinal Failure From Microvillus Inclusion Disease And Short Bowel Syndrome

Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders

Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs

Jaguar Health Announces Plans To Use AI Platforms To Support Development, Commercialization, Healthcare Delivery Objectives For Crofelemer Programs To Treat Intestinal Failure

Jaguar Health Inc (JAGX) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ...

Jaguar Health, Inc. (JAGX) Q4 2025 Earnings Call Prepared Remarks Transcript

Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates